PM101: A cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 167-172

  Cushing, Daniel J ^a   Kowey, Peter R ^b   Cooper, Warren D ^a   Massey, Bill W ^c   Gralinski, Michael R ^d   Lipicky, Raymond J ^e  

^a Prism Pharmaceuticals Inc   (United States)

^b LANKENAU HOSPITAL   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d CorDynamics ^*  (United States)

^e NONE

Author keywords

Amiodarone; Blood pressure; Cyclodextrin; Hemodynamic

Indexed keywords

AMIODARONE; BENZYL ALCOHOL; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CHLORALOSE; GLUCOSE; MORPHINE; PM 101; POLYSORBATE 80; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RATE; HEMODYNAMICS; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC VASCULAR RESISTANCE;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZYL ALCOHOL; BETA-CYCLODEXTRINS; BLOOD PRESSURE; CARDIAC OUTPUT; DOGS; EXCIPIENTS; FEMALE; GLUCOSE; HEART RATE; HYPOTENSION; INFUSIONS, INTRAVENOUS; MYOCARDIAL CONTRACTION; POLYSORBATES; SOLUBILITY;

EID: 62149086281     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.009     Document Type: Article

References (42)

1. Abraxis Pharmaceutical Products. Amiodarone Hydrochloride Injection [Prescribing Information]. 2008 (2008), Abraxis Pharmaceutical Products, Schaumburg, IL
2. Bicer S., Schwartz D.S., Nakayama T., and Hamlin R.L. Hemodynamic and electrocardiographic effects of graded doses of amiodarone in healthy dogs anesthetized with morphine/alpha chloralose. J. Vet. Intern. Med. 14 (2000) 90-95
3. Charlier R., Deltour G., Baudine A., and Chaillet F. Pharmacology of amiodarone, and anti-anginal drug with a new biological profile. Arzneimittelforschung. 18 (1968) 1408-1417
4. Charman S.A., Perry C.S., Chiu F.C.K., McIntosh K.A., Prankerd R.J., and Charman W.N. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J. Pharm. Sci. 95 (2006) 256-267
5. Connolly S.J., Latini R., and Kates R.E. Pharmacodynamics of intravenous amiodarone in the dog. J. Cardiovasc. Pharmacol. 6 (1984) 531-535
6. Cushing D.J., Adams M.P., Cooper W.D., Kowey P.R., and Lipicky R.J. PM101, a cyclodextrin-based IV formulation of amiodarone, is bioequivalent to Cordarone IV. J. Clin. Pharmacol. 48 (2008) 1120
7. Desai A.D., Chun S., and Sung R.J. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann. Intern. Med. 127 (1997) 294-303
8. Egan T.D., Kern S.E., Johnson K.B., and Pace N.L. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth. Analg. 97 (2003) 72-79
9. Elhasi S., Astaneh R., and Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur. J. Pharm. Biopharm. 65 (2007) 406-413
10. Fridericia L.S. The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta. Med. Scand. 53 (1920) 469-486
11. Gough W.B., Zeiler R.H., Barreca P., and El-Sherif N. Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs. J. Cardiovasc. Pharmacol. 4 (1982) 375-380
12. Helmy I., Herre J.M., Gee G., Sharkey H., Malone P., Sauve M.J., Griffin J.C., and Scheinman M.M. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J. Am. Coll. Cardiol. 12 (1988) 1015-1022
13. Holzgrefe H.H., Everitt J.M., and Wright E.M. Alpha-chlorolose as a canine anesthetic. Lab. Anim. Sci. 37 (1987) 587-595
14. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J. Cardiovasc. Electrophysiol. 14 (2003) 287-294
15. Kessler D., Palepu N., Tustian A., Rockwell K., Leo A., Hughes M.P., and Guthrie R. A novel amiodarone microemulsion injectable formulation. AAPS. Pharm. Sci. 4 (2002) W4122 (Abstract)
16. Kipp, J.E., Doty, M.J., Rebbeck, C.L., Eilert, J.Y., inventors; Baxter International, assignee. Amiodarone-containing parenteral administration. US Patent 6479541. November 12, 2002.
17. Kosinski E.J., Albin J.B., Young E., Lewis S.M., and Leland Jr. O.S. Hemodynamic effects of intravenous amiodarone. J. Am. Coll. Cardiol. 4 (1984) 565-570
18. Kowey P.R., Levine J.H., Herre J.M., Pacifico A., Lindsay B.D., Plumb V.J., Janosik D.L., Kopelman H.A., and Scheinman M.M. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 92 (1995) 3255-3263
19. Krantz J.C., Carr C.J., Bird J.G., and Cook S. Sugar alcohols: XXVI. Pharmacodynamic studies of polyoxyalkylene derivatives of hexitol anhdride partial fatty acid esters. J. Pharmacol. Exp. Ther. 93 (1948) 188-195
20. Kudenchuk P.J. Intravenous antiarrhythmic drug therapy in the resuscitation from refractory ventricular arrhythmias. Am. J. Cardiol. 84 (1999) 52R-55R
21. Lang R.M., Marcus R.H., Neumann A., Janzen D., Hansen D., Fujii A.M., B., and K.M. A time-course study of the myocardial mechanics. J. Appl. Physiol. 73 (1992) 143-150
22. Lessa M.A., and Tibirica E. Acute cardiodepressant effects induced by bolus intravenous administration of amiodarone in rabbits. Fund. Clin. Pharmacol. 19 (2004) 165-172
23. Levine J.H., Massumi A., Scheinman M.M., Winkle R.A., Platia E.V., Chilson D.A., Gomes A., and Woosley R.L. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. J. Am. Coll. Cardiol. 27 (1996) 67-75
24. Loftsson T., Jarho P., Masson M., and Jarvinen T. Cyclodextrins in drug delivery. Expert. Opin. Drug. Deliv. 2 (2005) 335-351
25. Masini E., Planchenault J., Pezziardi F., Gautier P., and Gagnol J.P. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents. Actions. 16 (1985) 470-477
26. Newton P.E., and Erk S.D. Hypotensive effect of Tween 80 in dogs. Physiologist 244 (1981) (Abstract)
27. Path G.J., Dai X.Z., Schwartz J.S., Benditt D.G., and Bache R.J. Effects of amiodarone with and without polysorbate 80 on myocardial oxygen consumption and coronary blood flow during treadmill exercise in the dog. J. Cardiovasc. Pharmacol. 18 (1991) 11-16
28. Petta J.M., and Zaccheo V.J. Comparative profile of L 3428 and other antianginal agents on cardiac hemodynamics. J. Pharmacol. Exp. Ther. 176 (1971) 328-338
29. Platou E.S., and Refsum H. Acute electrophysiologic and blood pressure effects of amiodarone and its solvent in the dog. Acta. Pharmacol. Toxicol. 58 (1986) 163-168
30. Salgado H.C., Simoes G.M., Filho V.J.S., daSilva V.J.D., Salgado M.C.O., and Fazan R. Negative inotropic and lusitropic effects of intravenous amiodarone in conscious rats. Clin. Exptl. Pharmacol. Physiol. 34 (2007) 870-875
31. Scheinman M.M., Levine J.H., Cannom D.S., Friehling T., Kopelman H.A., Chilson D.A., Platia E.V., Wilber D.J., and Kowey P.R. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation. 92 (1995) 3264-3272
32. Somberg J.C., Bailin S.J., Haffajee C.I., Paladino W.P., Kerin N.Z., Bridges D., Timar S., and Molnar J. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am. J. Cardiol. 90 (2002) 853-859
33. Somberg J.C., Cao W., Cvetanovic I., Ranade V., and Molnar J. Pharmacology and toxicology of a new aqueous formulation of intravenous amiodarone (Amio-Aqueous) compared with Cordarone IV. Am. J. Ther. 12 (2005) 9-16
34. Somberg J.C., Cvetanovic I., Ranade V., and Molnar J. Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute Cordarone I.V. infusion on mean arterial blood pressure in conscious dogs. Cardiovasc. Drugs. Ther. 18 (2004) 345-351
35. Somberg J.C., Timar S., Bailin S.J., Lakatos F., Haffajee C.I., Tarjan J., Paladino W.P., Sarosi I., Kerin N.Z., Borbola J., Bridges D.E., and Molnar J. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am. J. Cardiol. 93 (2004) 576-581
36. Sugiyama A., Satoh Y., and Hashimoto K. Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model. Jpn. J. Pharmacol. 87 (2001) 74-82
37. Talajic M., DeRoode M.R., and Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation. 75 (1987) 265-271
38. Torres-Arraut E., Singh S., and Pickoff A.S. Electrophysiologic effects of Tween 80 in the myocardium and specialized conduction system of the canine heart. J. Electrocardiol. 17 (1984) 145-151
39. Varma R.K., Kaushal R., Junnarkar A.Y., Thomas G.P., Naidu M.U., Singh P.P., Tripathi R.M., and Shridhar D.R. Polysorbate 80: a pharmacological study. Arzneimittelforschung. 35 (1985) 804-808
40. Wilton N.C., Hantler C.B., Landau S.N., Larson L.O., and Knight P.R. Effects of the volatile anesthetic agents on sinus node function and atrioventricular conduction in dogs: a comparison with chloralose anesthesia. J. Cardiothorac. Anesth. 2 (1988) 188-193
41. Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr. Womens. Health. Rep. 2 (2002) 105-109
42. Yasaka W.J., Eichbaum F.W., and Oga S. Antiarrhythmic effects of solvents: III. Effects of propylene glycol and benzyl alcohol on contractile force of isolated rabbit heart. Cardiovasc. Res. 13 (1979) 717-722